Omalizumab is a humanised monoclonal antibody produced using recombinant DNA that selectively binds to immunoglobulin (IgE).
Omalizumab binds to IgE and blocks its interaction with a high affinity FcεRI receptor. Thus, there is a decrease in the amount of free IgE, which is a triggering factor for the cascade of allergic reactions.
Omalizumab is the only class of biological anti-IgE therapy recommended for the treatment of atopic bronchial asthma; it helps withdraw or reduce the intake of glucocorticosteroids and also reduces the number and incidence of exacerbations.
In the treatment of moderate to severe persistent atopic bronchial asthma insufficiently controlled by the use of inhaled glucocorticosteroids in patients at the age of 6 years and older.
In the treatment of chronic idiopathic urticaria treatment resistant to H1-histamine receptor blockers in patients at the age of 12 years and older.